Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.
Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trněný M, Sharman JP, Herbaux C, Burke JM, Matasar M, Rai S, Izutsu K, Mehta-Shah N, Oberic L, Chauchet A, Jurczak W, Song Y, Greil R, Mykhalska L, Bergua-Burgués JM, Cheung MC, Pinto A, Shin HJ, Hapgood G, Munhoz E, Abrisqueta P, Gau JP, Hirata J, Jiang Y, Yan M, Lee C, Flowers CR, Salles G. Tilly H, et al. Among authors: herbaux c. N Engl J Med. 2022 Jan 27;386(4):351-363. doi: 10.1056/NEJMoa2115304. Epub 2021 Dec 14. N Engl J Med. 2022. PMID: 34904799 Clinical Trial.
Bendamustine is effective in T-cell prolymphocytic leukaemia.
Herbaux C, Genet P, Bouabdallah K, Pignon JM, Debarri H, Guidez S, Betrian S, Leleu X, Facon T, Morschhauser F, Damaj G, Cazin B, Ysebaert L. Herbaux C, et al. Br J Haematol. 2015 Mar;168(6):916-9. doi: 10.1111/bjh.13175. Epub 2014 Oct 15. Br J Haematol. 2015. PMID: 25316212 Free article. No abstract available.
Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study.
Reboursiere E, Le Bras F, Herbaux C, Gyan E, Clavert A, Morschhauser F, Malak S, Sibon D, Broussais F, Braun T, Fornecker LM, Garidi R, Tricot S, Houot R, Joly B, Abarah W, Choufi B, Pham AD, Gac AC, Fruchart C, Marin E, Safar V, Parcelier A, Maisonneuve H, Bachy E, Cartron G, Jaccard A, Tournilhac O, Rossi C, Schirmer L, Martignoles JA, Gaulard P, Tilly H, Damaj G; From the Lymphoma Study Association (LYSA) centers. Reboursiere E, et al. Among authors: herbaux c. Oncotarget. 2016 Dec 20;7(51):85573-85583. doi: 10.18632/oncotarget.10764. Oncotarget. 2016. PMID: 27458168 Free PMC article.
Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma.
Herbaux C, Gauthier J, Brice P, Drumez E, Ysebaert L, Doyen H, Fornecker L, Bouabdallah K, Manson G, Ghesquières H, Tabrizi R, Hermet E, Lazarovici J, Thiebaut-Bertrand A, Chauchet A, Demarquette H, Boyle E, Houot R, Yakoub-Agha I, Morschhauser F. Herbaux C, et al. Blood. 2017 May 4;129(18):2471-2478. doi: 10.1182/blood-2016-11-749556. Epub 2017 Mar 7. Blood. 2017. PMID: 28270452 Free article. Clinical Trial.
Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO/GS-4059.
Walter HS, Jayne S, Rule SA, Cartron G, Morschhauser F, Macip S, Karlin L, Jones C, Herbaux C, Quittet P, Shah N, Hutchinson CV, Fegan C, Yang Y, Mitra S, Salles G, Dyer MJS. Walter HS, et al. Among authors: herbaux c. Blood. 2017 May 18;129(20):2808-2810. doi: 10.1182/blood-2017-02-765115. Epub 2017 Apr 4. Blood. 2017. PMID: 28377400 Free PMC article. Clinical Trial. No abstract available.
Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia.
Dimopoulos MA, Tedeschi A, Trotman J, García-Sanz R, Macdonald D, Leblond V, Mahe B, Herbaux C, Tam C, Orsucci L, Palomba ML, Matous JV, Shustik C, Kastritis E, Treon SP, Li J, Salman Z, Graef T, Buske C; iNNOVATE Study Group and the European Consortium for Waldenström’s Macroglobulinemia. Dimopoulos MA, et al. Among authors: herbaux c. N Engl J Med. 2018 Jun 21;378(25):2399-2410. doi: 10.1056/NEJMoa1802917. Epub 2018 Jun 1. N Engl J Med. 2018. PMID: 29856685 Free article. Clinical Trial.
Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: A series from Lysa centers.
Rossi C, Gilhodes J, Maerevoet M, Herbaux C, Morschhauser F, Brice P, Garciaz S, Borel C, Ysebaert L, Obéric L, Lazarovici J, Deau B, Dupuis J, Chauchet A, Abraham J, Bijou F, Stamatoullas-Bastard A, Malfuson JV, Golfier C, Laurent C, Pericart S, Traverse-Glehen A, Kanoun S, Filleron T, Casasnovas RO, Ghesquières H. Rossi C, et al. Among authors: herbaux c. Am J Hematol. 2018 Jun 8. doi: 10.1002/ajh.25154. Online ahead of print. Am J Hematol. 2018. PMID: 29884994 Free article.
Development and validation of an UHPLC-MS/MS method for simultaneous quantification of ibrutinib and its dihydrodiol-metabolite in human cerebrospinal fluid.
Beauvais D, Goossens JF, Boyle E, Allal B, Lafont T, Chatelut E, Herbaux C, Morschhauser F, Genay S, Odou P, Danel C. Beauvais D, et al. Among authors: herbaux c. J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Sep 1;1093-1094:158-166. doi: 10.1016/j.jchromb.2018.06.026. Epub 2018 Jun 15. J Chromatogr B Analyt Technol Biomed Life Sci. 2018. PMID: 30029202 Free article.
91 results